Kongress der American Brachytherapy Society in Boston 2008

nterstitial low-dose-rate mono-brachytherapy with I125 - relapse-free survival and dosimetric outcome for localised prostate cancer in a single European institution

Neubauer S1,2,Derakhshani P1,2, Weise C1,3, Spira G1,3

  1. West German Prostate Center, Cologne, Germany
  2. Department of Urology, Klinik am Ring, Cologne
  3. Department of Radiooncology, Klinik am Ring, Cologne 

Introduction and Objective: 

To report tumor control and correlation to dosimetric results for patients with localized prostate treated with I-125 permanent seed implantation in a single European institution. This paper reports preliminary data on PSA outcome with a follow-up of up to 7 years.

Materials and methods:

651 patients with localised prostate cancer at stage T1-T2 received transperineal seed implantation with real-time intraoperative planning as monotherapy between December 2000 and December 2004 and were eglible for statistical analysis.

A total of 501 (76.9%) patients met the low-risk group definition, 148 (22.8%) were in the intermediate-risk and 2 (0.3%) in the high-risk group. Gleason score 6 or less was found in the majority of patients (n=599/92%) and clinical stage was T1a-b in 1.4%, T1c in 68%, T2a in 27% and T2b in 1.1%. 


Median follow-up time was 52.7 (range: 35.3-84.0) months. The 5-year PSA relapse-free survival (PRFS) outcome for low-risk and intermediate-risk patients according to the ASTRO definition was 97.5% and 94%, respectively. Median V100 Prostate was 98% and a median D90 Prostate of 177 Gy was achieved. The D90 was >130/140/150/160 Gy in 98.2/93.9/90.4 and 85.6% of patients. The median urethral D30 was 199.3 Gy and D10 rectal dose was 88.2 Gy. Patients with PSA-relapse were found to have a median D90 of 167.8 Gy, whereas the patients with PRFS had a median D90 of 175.9Gy. Patients were stratified to PSA nadir 0.5 ng/mL with the 5-year PRFS being 98.2% and 87.6%. Subanalaysis of the low-risk group showed a 5-year PRFS for PSA nadir 0.5 ng/mL of 97.9% and 92.1%.


The results of our study show that outcome of permanent seed implantation relates to pre-treatment PSA, tumor stage, Gleason score and dosimetric quality. A PSA nadir < 0.5 ng/mL was strongly related to long-term PSA relapse-free survival. In our series D90 Prostate, as a reflection of implant quality, was the strongest factor that impacts outcome.The use of real-time intraoperative planning optimizes high dose coverage of the target and can achieve an optimal therapeutic ratio between prostate and structures at risk. Biochemical control outcomes were excellent at 5 years and showed that the American data can be reproduced by European high-volume centers.

Prospective study on quality-of-life and toxicity of high-dose-rate brachytherapy as an interstitial boost for localized prostate cancer

Derakhshani P (1,2), Neubauer S (1,2), Weise C (1,3), Spira G (1,3)

  1. West German Prostate Center, Cologne, Germany
  2. Department of Urology, Klinik am Ring, Cologne
  3. Department of Radiooncology, Klinik am Ring, Cologne

Background and purpose: We report on the outcome, toxicities and quality-of-life (QoL) of patients after high-dose-rate (HDR)-brachytherapy as a boost to external beam radiotherapy (EBR) for intermediate and high risk localized prostate cancer.

Materials and methods: 416 patients were treated in a single institution with HDR-brachytherapy in afterloading-technique as a boost to 3D-conformal EBR (50.4 Gy) between April 2003 and December 2006. Patients were classified as low-risk in 7.8%, intermediate-risk in 40.1% and high-risk in 52.1%. 53% of patients received neoadjuvant or adjuvant androgen deprivation therapy. Patients were followed in terms of PSA-levels, QoL, urinary function and sexual status. Validated questionnaires (IPSS; EORTC QLQ C30, PR25-Prostate-Module, IIEF5) were prospectively administered to all patients before and at 1, 3, 6, 12 and 24 months after treatment.

Results: Median follow-up of patients was 34 months (12-56 months). Median PSA for intermediate-risk and high-risk groups decreased from initially 11 ng/ml to 0.15 ng/ml after 36 months. 3-year biochemical control rate for hormone naive patients, as defined by the ASTRO, was 87%. Urinary function (before HDR mean IPSS 8.9) worsened at 3, 6 and 12 months after HDR but remained stable (mean IPSS 10.6/9.3/10.3). Urinary bother score (UB) in PR25 was 30.17 immediately after HDR and improved significantly over the next twelve months (mean UB 23.61) to almost baseline 19.05 at 24 months. There was no change in bowel function (BF) throughout the study period (before HDR score 4.06, after HDR mean score 5.81). General health status (GHS) before HDR was excellent (score 72.41) and showed only slight decrease at all intervals after HDR (mean score 67.25). At 24 months patients reached baseline in GHS with a mean score of 69.84.

Conclusions: Combined HDR-brachytherapy for intermediate and high-risk prostate cancer results in excellent biochemical control and quality of life with minor acute or late complications.

Termin vereinbaren

Wir nehmen Ihre Terminanfrage gerne per Telefon oder Kontaktformular entgegen.

+49 (0)221 / 924 24 470Kontaktformular